Disease · MONDO_0005096

squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. squamous cell carcinoma. Diseases, record MONDO_0005096. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005096

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0005096; Open Targets
Other names: SCC, carcinoma, squamous cell, malignant, epidermoid carcinoma, epidermoid cell cancer, malignant epidermoid cell neoplasm, malignant epidermoid cell tumor, malignant epidermoid cell tumour, malignant squamous cell neoplasm, malignant squamous cell tumor, malignant squamous cell tumour, squamous carcinoma, squamous cell cancer, squamous cell carcinoma (morphologic abnormality), squamous cell carcinoma NOS (morphologic abnormality), squamous cell epithelioma; Open Targets
Disease Ontology: DOID:1749; Disease Ontology
MeSH: D002294; MeSH
NCI Thesaurus: C2929; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 100 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs100

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CETUXIMAB	CHEMBL1201577	Antibody	Approval	DailyMed	13	12	12	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Approval	DailyMed, EMA Human Drugs and FDA	3	0	0	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Approval	DailyMed	2	0	0	Drugs and targets
PODOFILOX	CHEMBL61	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TECHNETIUM TC 99M TILMANOCEPT	CHEMBL2108726	Protein	Approval	DailyMed	1	0	0	Drugs and targets
TEMOPORFIN	CHEMBL500576	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	16	16	15	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets

1 to 10 of 100

See all 100 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	9	Epidermal growth factor receptor erbB1 inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	8	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
TYMS	Thymidylate synthase	4	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	3	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 69

See all 69 targets

Trials88

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00946712	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	Phase 3	1,333	2019-03-07	Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma	BEVACIZUMAB, CARBOPLATIN, CETUXIMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01265849	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity	Phase 3	928	2022-08-19	Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate	CYCLOPHOSPHAMIDE, INDOMETHACIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00300885	A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)	Phase 3	926	2010-09-20	Carcinoma, Non-Small Cell Lung	CARBOPLATIN, PACLITAXEL, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02252042	Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)	Phase 3	495	2018-08-13	Head and Neck Squamous Cell Cancer	PEMBROLIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00002975	Photodynamic Therapy in Treating Patients With Skin Cancer	Phase 2	180	2013-10-10	Non-melanomatous Skin Cancer, Precancerous Condition	AMINOLEVULINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00573131	Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer	Phase 2	137	2014-05-16	Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma	CISPLATIN, FLUOROURACIL, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03058289	A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6	Phase 1/2	111	2024-08-13	Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma	CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02383927	Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations	Phase 2	63	2024-07-11	Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor	TIPIFARNIB	Its record names the disease	ClinicalTrials.gov
NCT00453336	Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract	Phase 2	45	2013-10-18	Head and Neck Cancer, Precancerous/Nonmalignant Condition	PORFIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00343083	Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)	Phase 2	43	2014-04-09	Cancer of Head and Neck	CARBOPLATIN, CETUXIMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 88

See all 88 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause	593 of 657	570 of 656	1,313	NCT00946712	Trial comparisons
Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events	66 of 632	97 of 627	1,259	NCT00946712	Trial comparisons
Sorafenib + C/P vs Placebo + C/P: serious adverse events	272 of 463	195 of 459	922	NCT00300885	Trial comparisons
Pembrolizumab vs Standard Treatment: Number of Participants Who Experienced At Least One Adverse Event (AE) in All Participants	240 of 246	227 of 234	480	NCT02252042	Trial comparisons
Pembrolizumab vs Standard Treatment: Number of Participants Who Discontinued Study Treatment Due to an AE in All Participants	30 of 246	36 of 234	480	NCT02252042	Trial comparisons
Pembrolizumab vs Standard Treatment: Number of Participants Who Experienced At Least One AE in Participants With PD-L1 ≥1% CPS	193 of 195	178 of 183	378	NCT02252042	Trial comparisons
Pembrolizumab vs Standard Treatment: Number of Participants Who Discontinued Study Treatment Due to an AE in Participants With PD-L1 ≥1% CPS	25 of 195	29 of 183	378	NCT02252042	Trial comparisons
Group 1 vs Group 2: serious adverse events	30 of 72	20 of 65	137	NCT00573131	Trial comparisons
Arm A vs Arm B: deaths from any cause	4 of 19	2 of 17	36	NCT03738228	Trial comparisons
Arm A vs Arm B: serious adverse events	6 of 19	7 of 17	36	NCT03738228	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials86

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39400600	RESULT	1	PubMed
30285770	RESULT	1	PubMed
30280635	RESULT	1	PubMed
30206369	RESULT	1	PubMed
29658856	RESULT	1	PubMed
29658848	RESULT	1	PubMed
29570421	RESULT	1	PubMed
28885881	RESULT	1	PubMed
28397821	RESULT	1	PubMed
28271869	RESULT	1	PubMed

1 to 10 of 86

See all 86 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005096

GET https://conductscience.org/api/diseases/v1/MONDO_0005096/drugs?page=2

API reference For AI assistants